Abstract
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
Copyright © 2020. Published by Elsevier Inc.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Aminopyridines
-
Anaplastic Lymphoma Kinase / genetics
-
Crizotinib / therapeutic use
-
Humans
-
Lactams
-
Lactams, Macrocyclic
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / genetics
-
Pyrazoles
Substances
-
Aminopyridines
-
Lactams
-
Lactams, Macrocyclic
-
Pyrazoles
-
Crizotinib
-
Anaplastic Lymphoma Kinase
-
lorlatinib